ABSTRACT

Introduction

The use of nanoparticles for breast cancer targeting and treatment has become a reality. They are safe and possess interesting peculiarities such as the unspecific accumulation into the tumor site and the possibility to activate controlled drug release as compared to free drugs. However, there are still many areas of improvement which can certainly be addressed with the use of peptide-based elements.

Areas covered

The article reviews different preclinical strategies employing peptides and proteins in combination with nanoparticles for breast cancer targeting and treatment as well as peptide and protein-targeted encapsulated drugs, and it lists the current clinical status of therapies using peptides and proteins for breast cancer.

Expert opinion

The conjugation of protein and peptides can improve tumor homing of nanoparticles, increase cellular penetration and attack specific drivers and vulnerabilities of the breast cancer cell to promote tumor cytotoxicity while reducing secondary effects in healthy tissues. Examples are the use of antibodies, arginylglycylaspartic acid (RGD) peptides, membrane disruptive peptides, interference peptides, and peptide vaccines. Although their implementation in the clinic has been relatively slow up to now, we anticipate great progress in the field which will translate into more efficacious and selective nanotherapies for breast cancer.

中文翻译：

---

肽，蛋白质和纳米技术：在乳腺癌靶向和治疗方面有希望的协同作用。

摘要

介绍

纳米粒子用于乳腺癌的靶向和治疗已成为现实。它们是安全的，并且具有有趣的特性，例如与游离药物相比，非特异性地积累到肿瘤部位中以及激活受控药物释放的可能性。然而，仍然有许多改进领域可以肯定地通过使用基于肽的元件来解决。

覆盖区域

本文回顾了将肽和蛋白质与纳米粒子结合用于乳腺癌靶向和治疗以及以肽和蛋白质靶向的封装药物的不同临床前策略，并列出了使用肽和蛋白质治疗乳腺癌的当前临床状况。

专家意见

蛋白质和肽的缀合可以改善纳米颗粒的肿瘤归巢，增加细胞渗透性并攻击乳腺癌细胞的特定驱动力和脆弱性，从而促进肿瘤细胞毒性，同时减少健康组织的继发作用。实例是抗体，精氨酰基糖基天冬氨酸（RGD）肽，膜破坏性肽，干扰肽和肽疫苗的使用。尽管到目前为止，它们在临床中的实施相对较慢，但我们预计该领域将取得巨大进展，这将转化为对乳腺癌更有效和更具选择性的纳米疗法。